A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.
A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values. So, [we all need to] come together, explains Bo Gamble, Director Of Strategic Practice Initiatives at the Community Oncology Alliance.
Transcript:
How does COA view "value" in oncology, and how is that distinction determined?
That’s a great question, it’s a question that we get asked often. COA’s perspective on value is let’s ask all [of] the different stakeholders, and let’s try to come up with a model that can meet that statement, or meet the value guide for everybody whether they’re a patient or an employer like we heard about today. A patient has their own set of values, providers have their own set of values, and the people that pay for it have their own set of values.
So, let’s come together, let’s make sure we understand that so the model that we have that we present, [and then] present all the options for whatever your definition may be. To us, there’s no simple definition. But the model, the payment system, the delivery system, needs to consider all of the different aspects of value.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen